已发表论文

aMAP 评分作为 HBV 相关性急慢性肝衰竭患者长期预后的预测指标

 

Authors Sun Y , Li Z , Liao G, Xia M, Xu X , Cai S , Peng J

Received 9 October 2021

Accepted for publication 13 December 2021

Published 10 January 2022 Volume 2022:15 Pages 407—415

DOI https://doi.org/10.2147/IJGM.S343457

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Scott Fraser

Background and Aim: The longterm outcomes of patients with hepatitis B virus-related acute-on-chronic liver failure (HBVACLF) remain not well known. This study aimed to investigate whether aMAP score can predict re-hospitalization, hepatocellular carcinoma (HCC) occurrence and long-term mortality in patients with HBV-ACLF.
Methods: A total of 82 patients diagnosed with HBV-ACLF and survived over 6 months were enrolled. The median follow-up period was 105 (75.9, 134.1) months. The Cox proportional hazards or logistic regression analysis was used to determine independent risk factors. Cumulative incidence of HCC and survival rate were evaluated using Kaplan–Meier analysis.
Results: Multivariate analysis identified that the aMAP risk score was an independent predictor of re-hospitalization (odds ratio [OR] = 1.112, 95% confidence interval [CI]:  1.021– 1.211, p = 0.015), hepatocellular carcinoma occurrence (hazards ratio [HR] = 2.277, 95% CI:  1.014– 5.114, p = 0.046) and mortality (HR = 1.366, 95% CI:  1.040– 1.794, p = 0.025). High-risk aMAP scores were associated with higher risk of HCC occurrence and mortality.
Conclusion: A higher aMAP score was an independent risk predictor of re-hospitalization, HCC occurrence and mortality, respectively, in HBV-ACLF patients who survived over 6 months, which can be applicable for early risk stratification and clinical decision.
Keywords: acute-on-chronic liver failure, chronic hepatitis B virus infection, re-hospitalization, hepatocellular carcinoma, mortality, prognosis